Celltrion leads biosimilars in Asia, biosimilars in Europe expand, while Sandoz restructures and FDA hurdles loom.
Biologics eat 51% of drug spending despite 5% of prescriptions, but FDA's new draft guidance hopes more competition can close that gap.
Budget impact analysis finds omalizumab biosimilars in Europe could cut payer costs by €641M in 5 years, expanding access and ...
A new analysis dives into why Europe’s eye clinics lag on biosimilars and how education, guidance, and smarter tenders could unlock €747 million in savings.
CHMP backs a fifth teriparatide biosimilar as biosimilars in Europe grow, while US patent fights threaten new biologic competition.
A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results